Inherited retinal diseases: Therapeutics, clinical trials and end points—A review

M Georgiou, K Fu**ami… - Clinical & Experimental …, 2021 - Wiley Online Library
Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous group of
disorders characterised by photoreceptor degeneration or dysfunction. These disorders …

[HTML][HTML] Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives

AV Garafalo, AV Cideciyan, E Héon, R Sheplock… - Progress in retinal and …, 2020 - Elsevier
Due to improved phenoty** and genetic characterization, the field of 'incurable'and
'blinding'inherited retinal diseases (IRDs) has moved substantially forward. Decades of …

Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial

MD Fischer, S Michalakis, B Wilhelm… - JAMA …, 2020 - jamanetwork.com
Importance Achromatopsia linked to variations in theCNGA3gene is associated with day
blindness, poor visual acuity, photophobia, and involuntary eye movements owing to lack of …

Gene therapy for inherited retinal diseases

Y Nuzbrokh, SD Ragi, SH Tsang - Annals of Translational …, 2021 - pmc.ncbi.nlm.nih.gov
Inherited retinal diseases (IRDs) are a genetically variable collection of devastating
disorders that lead to significant visual impairment. Advances in genetic characterization …

Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial

FF Reichel, S Michalakis, B Wilhelm, D Zobor… - British Journal of …, 2022 - bjo.bmj.com
Aims To determine long-term safety and efficacy outcomes of a subretinal gene therapy for
CNGA3-associated achromatopsia. We present data from an open-label, nonrandomised …

[HTML][HTML] First-in-human gene therapy trial of AAV8-hCARp. hCNGB3 in adults and children with CNGB3-associated achromatopsia

M Michaelides, N Hirji, SC Wong, CG Besirli… - American Journal of …, 2023 - Elsevier
Purpose To assess the safety and efficacy of AAV8-hCARp. hCNGB3 in participants with
CNGB3-associated achromatopsia (ACHM). Design Prospective, phase 1/2 …

Full-field stimulus threshold testing: a sco** review of current practice

LF Shi, AJ Hall, DA Thompson - Eye, 2024 - nature.com
The full-field stimulus threshold (FST) is a psychophysical measure of whole-field retinal
light sensitivity. It can assess residual visual function in patients with severe retinal disease …

Gene therapy for color blindness

MM Hassall, AR Barnard… - The Yale journal of …, 2017 - pmc.ncbi.nlm.nih.gov
Achromatopsia is a rare congenital cause of vision loss due to isolated cone photoreceptor
dysfunction. The most common underlying genetic mutations are autosomal recessive …

Adaptive optics retinal imaging in CNGA3-associated achromatopsia: retinal characterization, interocular symmetry, and intrafamilial variability

M Georgiou, KM Litts, A Kalitzeos… - … & Visual Science, 2019 - iovs.arvojournals.org
Purpose: To investigate retinal structure in subjects with CNGA3-associated achromatopsia
and evaluate disease symmetry and intrafamilial variability. Methods: Thirty-eight …

[HTML][HTML] Achromatopsia

S Kohl, H Jägle, B Wissinger, D Zobor - 2018 - europepmc.org
Achromatopsia is characterized by reduced visual acuity, pendular nystagmus, increased
sensitivity to light (photophobia), a small central scotoma, eccentric fixation, and reduced or …